Go to menu

Current Research Trials

Sydney Retina Clinic and Day Surgery is proud to be associated with a research department named the Sydney Institute of Vision Science. All members of the research team have a strong background in both clinical and laboratory research and are dedicated to the development of new treatment for retinal disease.

Sponsored Trials

ONS-5010-001 Study

A Clinical effectiveness, multicentre, randomized, double masked, active controlled study of the efficacy and safety of ONS-5010 in subjects with subfoveal Choroidal Neovascularization (CNV) secondary to age-related macular degeneration (AMD).


OPT-302 in combination with aflibercept for persistent central-involved Diabetic Macular Edema (DME).


The Rhine study is a phase III, multicenter, randomized, double-masked, active comparator-controlled study to evaluate the efficacy and safety of RO6867461 in patients with Diabetic Macular Edema (DME).


The OTX-TKI study is a phase 1 open-label, dose escalation study of OTX-TKI (axitinib implant) for intravitreal use in subjects with neovascular Age-related macular degeneration (AMD).


SEQUOIA is a global, randomised, active controlled study which evaluates the safety and efficacy of Abicipar as a treatment for Neovascular Age-Related Macular Degeneration (AMD).

Kestrel Study

A two-year, three arm, randomized, Double-Masked, Multicenter, Phase 3 study assessing the efficacy and safety of Brolucizumab versus Aflibercept in adult patients with visual impairment due to Diabetic Macular Edema (DME).

EC-FCA-001 Study

Study of safety and tolerability of intravitreal Fludrocortisone Acetate (FCA) in patients with Geographic Atrophy (GA).

Panda Study

A multicentre, double-masked, randomized, dose-ranging trial to evaluate the efficacy and safety of Conbercept intravitreal injection in subjects with Neovascular Aged-related Macular Degeneration (AMD).

Upcoming Trials:

 ISIS 696844-CS5



Investigator Initiated Studies

Clinicopathological Correlation in Macular Degeneration.

Intravitreal Aflibercept for the treatment of treatment resistant retinal vein occlusions.